Trials shows bimekizumab response durable at four years for moderate-to-severe psoriasis
Patients with psoriasis treated with bimekizumab rapidly achieve high levels of clinical and health-related quality-of-life responses that are durable at four years, according to research presented at the annual meeting of ...
Mar 18, 2024
0
0